Insights from 2023 SITC Annual Meeting
SITC 2023 Insights: "CheckMate 816 Trial - Analysis of Pathologic Features and Efficacy Outcomes With Neoadjuvant Nivo + Platinum-Doublet Chemo for Resectable NSCLC"
By
Insights from 2023 SITC Annual Meeting
FEATURING
Julie Deutsch
By
Insights from 2023 SITC Annual Meeting
FEATURING
Julie Deutsch
Comments 0
Login to view comments.
Click here to Login
